RT Journal Article
T1 Influence of CMO pharmaceutical care model-based intervention on readmission rate in high risk HIV patients: the INFARDAR study
A1 Guzman Ramos, Maria Isabel
A1 Manzano Garcia, Mercedes
A1 De Las Aguas Robustillo-Cortes, Ma
A1 Gutierrez Pizarraya, Antonio
A1 Morillo-Verdugo, Ramon
K1 HIV
K1 Hospital readmission
K1 Pharmaceutical Care
K1 Patient discharge
K1 Continuity of care
K1 Infected patients
K1 Antiretroviral therapy
K1 Large cohort
K1 Validation
K1 Program
K1 Death
AB Background. Many studies have indicated that hospitalization and readmissions occur frequently, especially among people living with HIV. The aim of the study was to determine the effectiveness of a programmed and structured pharmaceutical intervention, based on "CMO PC model" to reduce the readmission rate in high-risk HIV patients.Material and methods. This was a single-center, prospective study based on a structured health intervention conducted between March-2017 and March-2018 with 12 months of follow-up at outpatient pharmacy services. At discharge, HIV patients included were classified according to the risk of readmission as low or high risk patients, being the latter proposed to participate. The selected patients were randomly assigned to a control group (usual care) or intervention group (including stratification-motivational interview and new technologies: CMO pharmaceutical care). The primary endpoint was readmission rate at one year of follow-up in each group.Results. A total of 39 patients were included. As regards the main variable, in the intervention group, 21,4% (n=3) of patients were readmitted in the first year after discharge vs. 66,7% (n=6) in the control group (p=0,042).Conclusions. Tailored pharmaceutical care based on risk stratification, motivational interviewing, and new technologies has a positive influence to reduce the percentage of readmission in high risk HIV patients.
PB Sociedad espanola quimioterapia
SN 0214-3429
YR 2021
FD 2021-10-01
LK https://hdl.handle.net/10668/26552
UL https://hdl.handle.net/10668/26552
LA en
DS RISalud
RD Apr 5, 2025